Monoclonal Antibodies & Biologics

Design → GMP, without detours

Main Hub: San Diego, CA (Southern California)
Scope: IgG1/IgG4 mAbs, bispecifics (IgG-like and fragment-based), Fc-fusions, and complex recombinant proteins; CHO/HEK CLD; perfusion and intensified fed-batch; Protein A and alternative captures; orthogonal polishing; viral safety; formulation (liquid/lyo and high-concentration SC); fill–finish; stability; PPQ readiness.

Monoclonal antibodies and advanced biologics succeed when the whole system works: the clone makes the right molecule, the process protects quality, the analytics read the truth, and the documents convince. MycoVista builds that system from the first conversation. We map QTPP → CQAs → CPPs on day one, then we design vector, host, upstream, downstream, and formulation so the product you intend is the product you release—under inspection, at scale.

Why teams choose MycoVista for mAbs & biologics

We use an established tone because regulators do: clear plans, named risks, and artifacts that stand up.

  • End-to-end ownership. CLD → USP (fed-batch, high-seed, perfusion) → DSP (capture/polish/viral safety/UF-DF) → formulation → aseptic DP—harmonized across two synchronized facilities under a unified digital QMS (ALCOA+).
  • Manufacturability by default. We won’t chase a headline titer that collapses Protein A, starves polishing windows, or triggers viral-filter “hockey sticks.” We design for headroom.
  • Analytics first. Orthogonal methods for identity, purity, potency, residuals, and stability; we trend and lock ranges only when evidence agrees.
  • One narrative. QTPP, control strategy, process description, & method files.

Background: what actually governs mAb & biologic success

Experience shows most late failures trace to a few themes:

  1. Clonality or stability gaps—origin cannot be defended, or quality drifts under real feeds and oxygen transfer.
  2. DSP mismatch—capture loads or polishing selectivity were never tested on true harvests.
  3. Analytics drift—method transfers changed the answers; orthogonal confirmation was missing.
  4. Formulation reality—high-concentration viscosity, filter recovery, or lyo collapse discovered too late.

We address all four up front with process-relevant screening, early DSP checks, orthogonal analytics, and formulation decisions anchored in data.

From QTPP to control strategy

We reverse-engineer from the patient dose and the reviewer’s checklist.

  • QTPP (what must be true): route/dose (IV or SC), presentation (vial/PFS; liquid/lyo), target potency and purity, acceptable aggregates/variants, viral and bioburden safety, stability windows, shipping.
  • CQAs (what we will measure): identity, purity (SEC-MALS), size variants, charge variants (icIEF/IEF), glycans (released/site-specific as justified), potency (cell-based or binding with Fc-effector if MoA demands), residuals (HCP/DNA/Protein A), endotoxin, sterility, mycoplasma (as applicable).
  • CPPs (what we can control): vector/host/selection; feed/temperature/osmolality; pH/DO/mixing/shear; capture loading/residence time; polishing gradients/ionic strength; viral inactivation pH/time; TFF TMP/cross-flow; formulation buffers and excipients; filtration ΔP/T; lyo shelf temps/pressures.

Deliverable: a phase-appropriate control strategy tying each CQA to a method and a unit operation—codified in protocols and batch records.

Molecule archetypes we support

  • Classical IgG1/IgG4 mAbs. Platform behaviors help; we still confirm charge/glycan windows and aggregation risks under process conditions.
  • Bispecifics (IgG-like, 2+1, fragment-based). We prioritize assembly fidelity, mismatch suppression, and purification routes that don’t torture yield.
  • Fc-fusions. Linker stability, proteolytic hotspots, and viscosity at use-strength drive upstream/DSP choices and formulation plans.
  • Complex proteins/enzymes. Secretion signals, folding aids, and shear discipline matter; DSP often leans on mixed-mode or HIC; potency is usually activity-linked, not just binding.

Cell line development (CLD) that scales cleanly

We treat CLD as engineering, not luck.

  1. Vector & host. Promoter/UTR tuning, secretion signals, isotype/hinge for mAbs and Fc-fusions; site-preferred or transposon-based integration for stability; GS/DHFR selection sized to metabolic load.
  2. Pools → clones with documented clonality. Imaging-verified single-cell cloning (or FACS) and process-relevant pool screens (feeds, temperature, osmolality) so early winners predict scale.
  3. Stability & manufacturability gates. Titer and qP plus glycan/charge windows, shear tolerance, filtration behavior; we check capture loading and polishing selectivity on real harvest before lock.
  4. Banking. cGMP MCB/WCB with mycoplasma/adventitious agents, identity, and stability enrollment; chain-of-custody in QMS.

Outcome: a line that produces the molecule you can actually release—consistently.

Upstream process development (fed-batch, intensified, perfusion)

We pick the mode that meets product and phase requirements, then prove it.

  • Fed-batch, done correctly. Feed profiles, temperature shifts, osmolality shaping, and anti-stress tactics designed to hit titer and protect DSP.
  • High-seed & N-1 perfusion. Throughput gains without surrendering control of aggregates or charge.
  • True perfusion. When residence time or quality demands it; cell-retention and bleed strategies sized for robustness and cleaning validation.

Controls: oxygen transfer engineered to real kLa limits; shear envelopes by impeller/tip speed/sparger; PAT (capacitance/spectroscopy + soft sensors) validated against reference analytics so daily decisions are objective.

Downstream designed with upstream (capture → polish → viral safety → UF/DF)

We size columns and filters on real harvests—not buffer fantasies.

  • Capture. Protein A where lifecycle cost, leachables, and caustic tolerance align; otherwise, alternative captures proven by breakthrough and cleaning data.
  • Polishing. IEX/HIC/mixed-mode selected by impurity maps; gradient and step logic documented for operator reality.
  • Viral safety. Low-pH inactivation on true intermediates; viral filtration with pressure-time modeling to avoid catastrophic flux loss.
  • UF/DF. MWCO by hydrodynamic radius; shear/osmotic stress avoided by staging; aggregation thresholds discovered in development, not at release.

Artifacts: mass balance, recovery tables, and orthogonal purity confirmation that survive inspection.

Analytics that read the truth (orthogonal by default)

We plan complementary methods so one convinces and two persuade.

  • Identity/purity: intact mass, peptide mapping (LC-MS), CE-SDS (R/NR), SEC-MALS, icIEF/IEF, and glycans (released, site-specific where justified).
  • Potency: cell-based assays aligned to MoA; Fc-effector (ADCC/CDC) when biology requires; binding kinetics where informative.
  • Residuals & safety: HCP, host DNA, Protein A ligand; endotoxin, sterility, mycoplasma (as applicable).
  • Stability: real/accelerated with stress (thermal, agitation, freeze–thaw, light) mapped to degradation pathways.

Lifecycle: method development → transfer (dual hubs) → qualification/validation; OOS/OOT governance; change control with comparability plans.

Formulation & presentation (liquid, high-concentration, or lyo)

We start with patient comfort and device reality, then we design backwards.

  • Liquid formulations. pH/ionic strength/excipients that protect potency and limit viscosity; surfactant and antioxidant use justified by data, not habit.
  • High-concentration SC. Viscosity management with excipient strategy and temperature control; syringeability verified; sterile filtration recovery proven.
  • Lyophilization. Cycle design from physics (collapse/eutectic, anneal, primary/secondary drying); residual moisture targets and reconstitution times locked; cake quality repeatable.

DP integration: filtration ΔP/T set to protect recovery; fill settings and nitrogen overlays tuned; CCIT methods and inspection sensitivities validated.

PPQ & validation readiness

We prefer operational calm to heroics.

  • Design space → recipes. Development ranges become batch records with interlocks and alarms.
  • Cleaning validation. Worst-case soils and MACO calculations; swab/rinse methods validated; lifecycle and periodic verification documented.
  • Viral clearance & hold-time studies. Phase-appropriate and protocolized; results tracked with statistics and trending.
  • Media fills/process simulations for aseptic steps with interventions and holds represented.

Result: a PPQ plan that feels like execution, not a gamble.

Facilities & scale

  • Mammalian single-use suites: 50 L and 250 L GMP, with benchtop and multi-thousand-liter perfusion footprints for late-stage/registration-intent programs.
  • DSP: pilot to GMP chromatography/TFF skids; viral filtration capabilities; validated sensors and data capture.
  • DP: isolator/RABS lines for vial/PFS, lyophilizers with shelf mapping; CCIT platforms; automated/manual inspection.
  • Cleanrooms: ISO 8/7 with positive pressure and HEPA; BSL-2 where required; validated utilities (HPW/clean steam/compressed air) with continuous trending.
  • Digital backbone: validated CDS/LIMS/ELN and eBMR/eBR; access controls and audit trails aligned to ALCOA+.

Program Onboarding (your first 30 days)

Speed helps only when outputs are inspection-grade. In month one you receive:

  1. A phase-appropriate control strategy mapping QTPP → CQAs (purity/variants, potency, residuals, viral/bioburden safety, stability) → CPPs (CLD, USP, DSP, formulation, DP).
  2. A DoE plan for USP/DSP and analytics with sampling plans and acceptance criteria; for DP, a filtration feasibility and (if needed) lyo hypothesis with key risks.
  3. A Gantt & risk map (FMEA) with decision gates to IND/registration; initial specification proposal and stability program aligned to shipping and presentation.

Start: share molecule class, potency model, dose/route, quality targets, and timeline. We return a design space, study plan, and a documented path to GMP.

Typical timelines (indicative, biology-gated)

  • CLD: pools → clones with documented clonality; stability under process conditions; early DSP checks.
  • USP/DSP development: feed/temperature/osmolality DoE, capture/polish selection and limits, viral safety and UF/DF mapping; analytics stack qualified.
  • Formulation/DP: filtration recovery, high-concentration or lyo feasibility, inspection and CCIT methods, label/pack/ship draft.
  • Lock & PPQ plan: process description, CPP ranges, validation protocols, and regulatory text.

We state gates and pass criteria; biology runs the clock.

Tech transfer & rescue for mAbs

  • Triage: batch/deviation history, method files, stability, change controls; EM/utility trends if DP involved.
  • Stabilize → optimize → re-lock: interim setpoints to stop failures; targeted DoE on true drivers; comparability for changes; lifecycle files updated.
  • Regulatory remediation: refreshed CMC sections; deviation narratives; validation and stability addenda ready for inspection.

ESG & supply chain

  • Sensible disposables: closed processing where it cuts risk/time; stainless where cleaning validation and cost win.
  • Criticals strategy: qualified alternates for resins, membranes, filters, and plastics—with comparability on file.
  • Material stewardship: audited suppliers for critical reagents (e.g., FBS where applicable); traceability embedded in QMS.

Deliverables

  • Control strategy (QTPP → CQAs → CPPs) and process description with design space and limits.
  • CLD dossier (clonality, stability) and banking package (MCB/WCB).
  • DSP package (mass balance, recovery, impurity clearance; viral safety; UF/DF).
  • Analytics files (methods; transfer; qualification/validation; trending).
  • Formulation/DP (filtration feasibility, high-concentration or lyo dossier, inspection & CCIT).
  • Stability protocols/data and CMC text for IND/IMPD/BLA.
  • Batch records (eBMR/eBR) with links to sensors, alarms, and interventions.

Frequently asked

Perfusion or fed-batch? We model both and choose what meets CQAs with the least complexity; if quality or cycle time demands perfusion, we build it.


How do you control glycan and charge? By design—feed/temperature/osmolality and residence time where needed; confirmed by icIEF and glycan profiling with predefined windows.


Can you handle bispecifics? Yes—assembly fidelity, purification realism, and operator-holdable settings are our priorities; we document the why.


High-concentration SC? We manage viscosity and syringeability; we prove filter recovery and set device-compatible specs.


Lyophilize or stay liquid? If lyo clearly wins stability or logistics, we do it. If liquid meets the truth of your chain, we keep it liquid—and document why.

Summary — why MycoVista for Monoclonal Antibodies & Biologics

Because a biologic is more than a sequence. It is a manufacturing system that must run cleanly, read clearly, and pass inspection. We design that system—clone to dose—so your team can move from Design → Data → Decision with confidence, in San Diego and Montréal, without detours.

MycoVista | San Diego, CA & Montréal, Canada
Start Program Onboarding → Share molecule class, quality targets, and route/phase. We’ll return a design space, control strategy, and a documented path to GMP.

EN / FR support available.